OKYO Pharma Announces Public Offering of Ordinary Shares
Rhea-AI Summary
OKYO Pharma (Nasdaq: OKYO) announced an underwritten public offering of ordinary shares on February 12, 2026. The company will sell all shares offered, with an underwriter option for up to 15% additional shares for 30 days. Piper Sandler is sole book-running manager.
The offering is subject to market conditions and may not be completed. Proceeds are intended primarily for clinical development, general corporate purposes and working capital. The sale is being made from a Form F-3 shelf registration declared effective on February 10, 2026.
Positive
- Access to capital for clinical development
- Shelf registration effective Feb 10, 2026 enables timely offering
- Underwriter support from Piper Sandler as sole book-runner
Negative
- Potential shareholder dilution from primary offering and 15% option
- Offering completion uncertain and dependent on market conditions
- Net proceeds unspecified—magnitude of dilution unclear to investors
News Market Reaction – OKYO
In the Feb 13 session, OKYO declined 19.35%, reflecting a significant negative market reaction. Argus tracked a peak move of +9.8% during that session. Argus tracked a trough of -22.4% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.1x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | ATM facility transition | Negative | -6.7% | Shifted ATM equity facility to Leerink Partners to enable ongoing share sales. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent capital-raising headlines, including ATM and shelf activity, have coincided with negative price reactions.
Over recent weeks, OKYO advanced urcosimod with FDA interactions, compassionate use authorization, and plans for Phase 2b/3 studies, generally met with modestly positive to mixed price moves. In contrast, financing-related steps have weighed on the stock. A prior offering-related update on Feb 11, 2026 about transitioning the ATM facility to Leerink Partners saw a -6.7% reaction. Today’s underwritten offering, drawn from the same capital-raising toolkit, fits this pattern of equity funding news coinciding with share-price pressure.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form f-3 regulatory
base prospectus regulatory
prospectus supplement regulatory
free writing prospectus regulatory
book-running manager financial
public offering price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the “Offering”). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up to an additional
Piper Sandler & Co. is acting as the sole book-running manager for the Offering.
The Company intends to use the net proceeds from the Offering primarily for clinical development of its product candidates, general corporate purposes and working capital.
The securities are being offered and sold pursuant to a shelf registration statement on Form F-3 (File No. 333-293145), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2026, and declared effective on February 10, 2026. The Offering is being made only by means of a prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus that the Company may file with the SEC. A preliminary prospectus supplement describing the terms of the proposed Offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. The final prospectus supplement relating to the Offering will be filed with the SEC and will also be available on the SEC’s website. Copies of the preliminary prospectus supplement, the final prospectus supplement (when available) and the accompanying base prospectus relating to the Offering can also be obtained from Piper Sandler & Co. at 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attn: Prospectus Department, or via email at prospectus@psc.com or telephone at (800) 747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.
Forward-Looking Statements
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the proposed terms of the proposed offering, completion, timing and size of the proposed offering and the expected use of proceeds from the offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering, risks disclosed in the section titled “Risk Factors” included in the preliminary prospectus supplement filed with the SEC on February 12, 2026, and risks disclosed in other documents the Company files from time to time with the SEC. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com
